Treatment of advanced non-small cell lung cancer
Treatment of advanced non-small cell lung cancer
复制标题
DOI：
10.1093/annonc/mdj919
复制
发表时间：
2006-01-01
影响因子：
50.5
通讯作者：
de Marinis, F
中科院分区：
文献类型：
--
作者：
De Petris, L;Crinò, L;de Marinis, F
在过去的十年中，晚期转移性非小细胞肺癌的治疗有了实质性的改善。如果说在90年代早期，人们仍然担心化疗在晚期环境中的真实的疗效优于单独的最佳支持治疗，那么临床研究的不断发展已经证明，活性抗癌药物不仅在一线环境中具有生存优势，而且最近甚至在两条化疗线失败后复发的患者中也具有生存优势。在高通量技术的前提下，转化研究的目标是在分子基础上表征患者和肿瘤。有了药物基因组学，就有可能准确地预测患者的预后，并根据单个患者的基因表型调整治疗策略。
In the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early 90s there was still concern about the real efficacy of chemotherapy over best supportive care alone in the advanced setting, constant developments in clinical research have demonstrated the survival advantage of active anti-cancer drugs not only in the first-line setting, but, lately, even in patients with recurrent disease after failure of two previous chemotherapy lines. With the premises of high throughput technologies, translational research is aiming to characterize patients and tumors on a molecular basis. With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients.